SCHEMBL1726567

SCHEMBL1726567

CCn1cc2c(Oc3ccc(S(N)(=O)=O)cc3)cc(C(=O)Nc3ccn(C)n3)cc2n1

nearest known ligand 0.63

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GCK P35557 20/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9991119 0.91 GCK (0.64) GCK
SCHEMBL1724533 0.85 GCK (0.86) GCK
SCHEMBL1724912 0.84 GCK (0.72) GCK
SCHEMBL9989543 0.84 GCK (0.67) GCK
SCHEMBL1723174 0.84 GCK (0.71) GCK
SCHEMBL1725719 0.84 GCK (0.71) GCK
SCHEMBL1724970 0.82 GCK (0.75) GCK
SCHEMBL9989556 0.80 GCK (0.76) GCK
SCHEMBL1727622 0.80 GCK (0.75) GCK
SCHEMBL1724732 0.78 GCK (0.75) GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406230-A1 SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS Pfizer Inc. (US) 2012-01-18 EP disclosed
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators CORBETT JEFFREY W (US) 2011-12-29 US disclosed
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators CORBETT JEFFREY W (US) 2011-12-29 US disclosed
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators CORBETT JEFFREY W (US) 2011-12-29 US disclosed
WO-2010103438-A1 SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS PFIZER INC. (US) 2010-09-16 WO disclosed
WO-2010103438-A1 SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS PFIZER INC. (US) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators GCKR, GCK, GALK1 GCK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.